United Therapeutics Q3 2025 Earnings Preview

* United Therapeutics (NASDAQ:UTHR [https://seekingalpha.com/symbol/UTHR]) is scheduled to announce Q3 earnings results on Wednesday, October 29th, before market open.
* The consensus EPS Estimate is $7.31 [https://seekingalpha.com/symbol/UTHR/earnings/estimates] (+14.4% Y/Y) and the consensus Revenue Estimate is $812.87M (+8.5% Y/Y).
* Over the last 3 months, EPS estimates have seen 2 upward revisions [https://seekingalpha.com/symbol/UTHR/earnings/revisions] and 3 downward. Revenue estimates have seen 2 upward revisions and 8 downward.

MORE ON UNITED THERAPEUTICS

* United Therapeutics Corporation (UTHR) Phase 3 TETON-2 Results Conference (Transcript) [https://seekingalpha.com/article/4826480-united-therapeutics-corporation-phase-3-teton-2-results-conference-call]
* United Therapeutics Corporation (UTHR) Phase 3 TETON-2 Results - Slideshow [https://seekingalpha.com/article/4826479-united-therapeutics-corporation-uthr-phase-3-teton-2-results-conference-slideshow]
* United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4825237-united-therapeutics-corporation-uthr-presents-at-bernstein-2nd-annual-global-healthcare]
* United Therapeutics succeeds in late-stage trial for Tyvaso against lung disorder [https://seekingalpha.com/news/4491019-united-therapeutics-posts-tyvaso-trial-win]
* MannKind rises as United Therapeutics exercises option for second inhalational drug [https://seekingalpha.com/news/4489631-mannkind-rises-united-therapeutics-expands-deal]